Deal Tracker · Countries

China pharma deals

31 pharma deals involving China — companies based there or deals covering the market — tracked by EPT: licensing, localization & joint ventures. Most active: Bio-Thera Solutions, Avalon Pharma, Arcera Life Sciences & Hikma Pharmaceuticals. Latest: Innogen Pharmaceuticals → Arcera Life Sciences (Licensing, 19 Nov 2026).

31
deals tracked
18
announced in 2026
$396.5m
disclosed value (3 deals)
55%
licensing, the top deal type
  • EPT has tracked 31 China pharma deals (2014–2026), 18 of them announced in 2026.
  • The most common structures are licensing (55%), localization (19%) & joint ventures (10%).
  • Values were disclosed for 3 of 31 deals, totalling $396.5m; the largest is Livzon → Imexpharm ($221m, 11 May 2026).
  • The most active companies: Bio-Thera Solutions (6), Avalon Pharma (3), Arcera Life Sciences (2) & Hikma Pharmaceuticals (2).

Most active companies

Bio-Thera Solutions (6) · Avalon Pharma (3) · Arcera Life Sciences (2) · Hikma Pharmaceuticals (2) · Julphar (2) · SaudiVax (2)

Countries involved

Saudi Arabia (10) · UAE (5) · Egypt (4) · Indonesia (3) · Malaysia (3) · Vietnam (3)

Largest disclosed deals

Questions

How many China pharma deals has EPT tracked?
31 as of 19 Nov 2026, covering 2014–2026; 18 were announced in 2026. The most recent is Innogen Pharmaceuticals → Arcera Life Sciences (Licensing, 19 Nov 2026).
What types of China pharma deals are most common?
Licensing: 17 (55%); Technology transfer / Localization: 6 (19%); Joint venture: 3 (10%); Partnership / Collaboration: 3 (10%).
Which companies are most active in China pharma deals?
Bio-Thera Solutions (6 deals), Avalon Pharma (3 deals), Arcera Life Sciences (2 deals), Hikma Pharmaceuticals (2 deals), Julphar (2 deals), SaudiVax (2 deals).
What is the largest disclosed China pharma deal?
Livzon → Imexpharm: $221m (M&A / Acquisition, 11 May 2026); Sinopharm, Sinovac & Kangtai Biological Technology → AltINFARM: $125m (Technology transfer / Localization, 22 Jan 2026); Shanghai Henlius Biotech → Eurofarma: $50.5m (Licensing, 11 May 2022). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)